annual meeting program - American Society of Clinical Oncology

4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM
Novel Therapies for Myeloma
Location: E354a
CME credit: 1.5
Track(s): Lymphoma and Plasma Cell Disorders
Saturday, June 5, 2010
Asher Alban Akmal Chanan-Khan, MD—Co-Chair
Roswell Park Cancer Institute
Shaji Kumar, MD—Co-Chair
Mayo Clinic
4:30 PM Results of an ongoing open-label, phase II study of carfilzomib in patients
with relapsed and/or refractory multiple myeloma (R/R MM). (Abstract #8000)
R. Vij, D. S. Siegel, J. L. Kaufman, A. J. Jakubowiak, A. K. Stewart, S. Jagannath,
V. Kukreti, M. H. Le, M. K. Bennett, M. Wang, The Multiple Myeloma Research
Consortium (MMRC)
4:45 PM Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in
patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple
myeloma (MM). (Abstract #8001)
J. F. San-Miguel, O. Sezer, D. S. Siegel, A. Guenther, J. Blade, I. W. Prosser,
B. Bengoudifa, M. Klebsattel, P. M. Bourquelot, K. C. Anderson
Discussion
5:00 PM Paul Gerard Guy Richardson, MD (Abstracts #8000–8001)
Dana-Farber Cancer Institute
Novel Proteosome and HDAC Inhibitors in Myeloma
5:15 PM Activity of pomalidomide plus dexamethasone (Pom/dex) in dual
lenalidomide/bortezomib refractory multiple myeloma (MM). (Abstract #8002)
M. Lacy, M. A. Gertz, S. R. Hayman, A. Dispenzieri, S. Kumar, J. Mikhael,
A. K. Stewart, J. Allred, S. J. Mandrekar, S. V. Rajkumar
5:30 PM Elotuzumab in combination with bortezomib in patients with
relapsed/refractory multiple myeloma: A phase I study. (Abstract #8003)
A. J. Jakubowiak, D. M. Benson Jr., W. Bensinger, D. S. Siegel, T. M. Zimmerman,
A. Mohrbacher, P. G. Richardson, D. Afar, A. K. Singhal, K. C. Anderson, Multiple
Myeloma Research Consortium
Discussion
5:45 PM Sagar Lonial, MD (Abstracts #8002–8003)
Winship Cancer Institute at Emory University
New Immunomodulatory Agents and Antibodies in Myeloma
185
SATURDAY